Drive pharmaceutical sales in an assigned area, providing oncology product information to physicians and healthcare stakeholders, gathering market insight, planning growth, and reporting progress.
About this role
The Director, Head of Value, Evidence & Access is a people-leadership role within the Integrated Market Access Team at Innovative Medicine Japan. It leads the value, evidence and access agenda for medicines, focusing on Japan health technology assessment (HTA) and evidence for access decisions. The role coordinates with Pricing, Policy, New Product Planning, MAF, R&D, Commercial, and regional and global market access teams.
It assesses potential Japan HTA designation during LRFP and other decisions, directs HTA preparation, submission and negotiation, and builds the evidence-generation strategy. It communicates Japan’s evidence needs, supports access decisions and HTA policy engagement, manages relationships with industry associations and academic key opinion leaders, and manages the team and budget. Required experience includes at least eight years in health economics or healthcare market access; knowledge of Japanese government and health or social-insurance strategy, health-economic and cost-effectiveness analysis, and evidence-generation methods; and experience building teams and managing people and budgets in complex matrix environments.
This is an AI-generated summary of the employer's original posting — details can be incomplete, out of date or simply wrong. Always confirm everything on the official posting before applying.